Slide 1: Q3 2025 Earnings Call Presentation
Q3 2025 Earnings Call Presentation November │ 2025 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Auna S.A. (“Auna” or the “Company”) solely for use at this presentation. This presentation is confidential to the recipient. Accordingly, any attempt to copy, summarize or distribute this presentation or any portion hereof in any form to any other pa
Slide 3: Today's Speakers
Today’s Speakers +30 +20 +25 Jesus Zamora Gisele Remy Lorenzo Massart Executive Chairman of the Board and Chief Financial Officer and Executive Vice President, Strategy and President Executive Vice President Equity Capital Markets • Member of the Board since 2008 and President • Chief Financial Offi
Slide 4: 3Q 2025 Highlights
3Q 2025 Highlights Adjusted EBITDA1 -5% FXN2 or -7% YoY with margin decreasing 1.3 p.p. to 20.8%. “The strength and Reported results impacted by depreciation of PEN/MXN (-5%) and PEN/COP (-4%) YoY resilience of Auna’s integrated Continued strong growth in Peru resulting from improved pricing mix in
Slide 5: Consolidated 3Q25 Revenue and Adjusted EBITDA
Adjusted EBITDA decreased 5% FXN YoY, with solid results in Peru and Colombia partially offsetting Mexico’s Consolidated 3Q25 Revenue (S/) Adjusted EBITDA(1) (S/) 1,117Mn 232 Mn -1% YoY -7% YoY +1% FXN YoY -5% FXN YoY Healthcare Services Oncosalud Peru Total Capacity Plan Oncology Oncology Bed Utili
Slide 6: Q3 2025 Results by Segment
Q3 2025 ~ cos a a od © @ OA WN qauna
Slide 7: Healthcare Services Mexico results impacted by softer demand
Healthcare Services Mexico results impacted by softer demand, information system implementations, and lower Auna Seguros, while margin remained strong External Revenue1 (S/ Mn, %) Adj. EBITDA and margin1,2 (S/ Mn, %) 24% of LTM Revenues 36% of LTM Adj. EBITDA 35.9% 34.2% 32.0% 29.0% 31.4% -4% (L.C)
Slide 8: Update of key initiatives in Mexico
Update of key initiatives in Mexico 1. Leadership & Organization 4. Payors Investing in local leadership with new senior hires adding Advancing discussions with major insurers to expand over 100 years of combined experience. preferred provider network participation starting in 2026. 2. Out-of Po
Slide 9: Peruvian healthcare outperforms, supported by pricing mix
Peruvian healthcare outperforms, supported by pricing mix, while Oncosalud added plan memberships and improved Oncology MLR to record 49.3% External Revenue1 (S/ Mn, %) Adj. EBITDA and margin1,2 (S/ Mn, %) 43% of LTM Revenues 43% of LTM Adj. EBITDA 21.6% 21.3% 22.7% 21.1% 22.0% +9% +3% +9% 474 488 1
Slide 10: Colombia improved results supported by risk-sharing models
Colombia improved results supported by risk-sharing models and payor diversification External Revenue1 (S/ Mn, %) Adj. EBITDA and margin1,2 (S/ Mn, %) 33% of LTM Revenues 23% of LTM Adj. EBITDA 16.7% 12.4% 13.9% 14.0% 14.3% +4% (L.C) +3% (L.C) +18% (L.C) 0% -4% +14% +6% (L.C) +4% (L.C) 1,090 -1% 1,0
Slide 11: Q3 2025 Consolidated Results
Q3 2025 Consolidated Results 11
Slide 12: Modest FXN growth as Oncosalud, HC Peru and HC Colombia improved revenues
Modest FXN growth as Oncosalud, HC Peru and HC Colombia improved revenues, partially offsetting lower revenues from Mexico’s operations and other non-operating impacts 3Q25 YoY revenues increased 9% in Peru, 4% in Colombia in L.C., while Mexico decreased -12% in L.C. Peru HC services grew due to
Slide 13: Adjusted EBITDA -5% FXN or -7% YoY
Adjusted EBITDA1 -5% FXN or -7% YoY due to strong growth in Peru and Colombia, offset by lower revenue in Mexico Adjusted EBITDA Margin1 decreased 1.3 pp YoY to 20.8% in 3Q25 PEN/MXN decline of 5% and PEN/COP decline of 4% YoY Adjusted EBITDA1 Bridge (S/ Mn, %) Consolidated Peru Adjusted 22.7% E
Slide 14: Adjusted Net Income decreased 23% YoY to S/58 million
Adjusted Net Income1 decreased 23% YoY to S/58 million Positive operating profit across segments except in Mexico Adjusted Net Income1 bridge: 3Q’24 vs 3Q’25 (S/ Mn) 75 58 63 31 21 17 11 Adjusted Adjusted EPS2 : EPS2 : S/ 0.98 S/ 0.71 Adj. Net Operating Profit Fx variance Net interest Income tax N
Slide 15: End of period cash remains at healthy levels
End of period cash remains at healthy levels Pre-tax operating cash flow2 grew 65% versus 2Q 2025 Free cash flow includes S/19 million in payments to Opción Oncología doctors and AR delays in Mexico due to ERP and Hospital Information systems migrations Cash flow bridge Free Cash Flow 1 S/321 (S
Slide 16: Maintained healthy debt structure and leverage ratio
Maintained healthy debt structure and leverage ratio while improving maturity profile through a refinancing Debt Structure Highlights Debt by Type (%) Debt by Currency (%) Successful debt refinancing for USD$ 765 million, including US$ 365 Consolidated Debt: S/ 3,655 million in aggregate principal
Slide 17: During the remainder of 2025, we will continue implementing our initiatives
“During the While each segment is at a different maturity stage, each Peru and Colombia have delivered strong results, supporting Mexico and remainder of demonstrating the strength of our diversified footprint. 2025, we will Despite its maturity, Peru continues making consistently strong contributio
Slide 18: Q&A
Q&A quna
Slide 19: Exhibits
Exhibits qunda
Slide 20: Consolidated Balance Sheet
Consolidated Balance Sheet (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Sep-25 Δ Sep-25 Sep-25 Dec-24 (USD) vs Dec-24 Liabilities Current liabilities Loans and borrowings 190 658 654 4 Lease liabilities 9 31 32 (1) Trade accounts payable 273 946 931 15 Other
Slide 21: Consolidated Statement of Income (1/2)
Consolidated Statement of Income (1/2) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) 3Q'25 Δ 3Q'25 vs Δ YTD 25 vs 3Q'25 YTD 25 (USD) 3Q'24 YTD 24 Revenue Healthcare Services Mexico 76 264 781 -16% -16% Healthcare Services Colombia 105 365 1,050 0% -4% - Health
Slide 22: Consolidated Statement of Income (2/2)
Consolidated Statement of Income (2/2) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) 3Q'25 Δ 3Q'25 vs Δ YTD 25 vs 3Q'25 YTD 25 (USD) 3Q'24 YTD 24 Share of profit of equity accounted investees 1 3 8 45% 24% Profit (loss) before tax 28 97 291 -24% 1.0x Income ta
Slide 23: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) YTD 25 Δ YTD 25 vs YTD 25 Δ YTD 25 vs YTD 25 YTD 24 YTD 25 YTD 24 (USD) YTD 24 (USD) YTD 24 Cash flows from operating activities Cash flows from investing activities (Loss) profit f
Slide 24: Adjusted EBITDA and Adjusted EBITDA Margin reconciliation
Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted EBITDA: is calculated as profit (loss) before tax for the period plus net finance cost, depreciation and amortization, pre- operating expenses for
Slide 25: Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (continued)
Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (continued) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) For the three months ended September 30, 2024 Healthcare Healthcare Consolidated Healthcare Oncosalud Holding and Services Services Reportable S
Slide 26: Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (continued)
Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (continued) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Year to date September 30, 2025 Healthcare Consolidated Healthcare Healthcare Oncosalud Holding and Services Reportable Services Mexico Services
Slide 27: Consolidated Peru Adjusted EBITDA and Adjusted EBITDA Margin reconciliation
Consolidated Peru Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Consolidated Peru Adjusted EBITDA: is calculated by adding Healthcare Services Peru Segment Adjusted EBITDA plus Oncosalud Peru Segment Ad
Slide 28: Adjusted Net Income reconciliation
Adjusted Net Income reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted Net Income: is calculated as profit (loss) for the period plus adjustments as described below. 3Q'25 3Q'25 3Q'24 YTD 25 YTD 24 (USD) Net Income (Loss) 15 53 101 175 100 (
Slide 29: Free Cash Flow
Free Cash Flow (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Free Cash Flow: is calculated by adding Net Cash Flows from Operations and Net Cash Flows used in Investment activities. Sep-24 Sep-25 Cash from Operating Activities 612,109 581,731 (-) Income tax 15
Slide 30: Adjusted Basic and Diluted Earnings per Share
Adjusted Basic and Diluted Earnings per Share (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted Basic and Diluted Earnings per Share: Adjusted Basic and Diluted Earnings per Share is calculated by dividing profit attributable to owners of Adjusted Net Inc
Slide 31: Net Debt reconciliation
Net Debt reconciliation (Figures in millions of Soles, unless expressed otherwise) Net Debt: We calculate Net Debt as Gross Debt minus Cash and cash equivalents. Sep-24 Dec-24 Sep-25 (+) Loans and borrowings 3,602 3,620 3,526 Short term debt 582 654 658 Long term debt 3,021 2,966 2,868 (+) Lease Lia
Slide 32: Leverage Ratio reconciliation
Leverage Ratio reconciliation (Figures in millions of Soles, unless expressed otherwise) Leverage Ratio: is calculated as (i) current and non-current loans and borrowings plus current and non-current lease liabilities minus (ii) cash and cash equivalents, divided by (iii) Last twelve months Adjusted
Slide 33: Key Operational Metrics – Oncosalud Peru & Healthcare Services
Key Operational Metrics – Oncosalud Peru & Healthcare Services 1) As of period end and as reported to the National Superintendence of Health Susalud. Includes Oncology plans and Health plans. Δ YTD 25 vs YTD 25 YTD 24 2) Includes active plan members and inactive members. Inactive members are defined
Slide 34: Trends in Key Financial Metrics
Trends in Key Financial Metrics (Figures in millions of Soles, unless expressed otherwise) 3Q'23 4Q'23 1Q'24 2Q'24 3Q'24 4Q'24 1Q'25 2Q'25 3Q'25 Revenue Oncosalud Peru 237 244 253 269 273 276 281 286 294 Healthcare Services Peru 230 225 241 255 255 245 263 269 279 Healthcare Services Colombia 324 33
Slide 35: Investor Relations
Investor Relations contact@aunainvestors.com www.aunainvestors.com 35